An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder

Bibliography

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Text Revision (DSM-IV-TR). Am Psychiatry Assoc; Washington, DC: 2000
   Google Scholar
• Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children - United States, 2003 and 2007. Morb Mortal Wkly Rep 2010;59(44):1439-43
   PubMedGoogle Scholar
• Pliszka SR. Practice Parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921
   PubMed Web of Science ®Google Scholar
• FDA: Approval Letter. Drug Approval Package: Vyvanse (Lisdex- amfetamine dimesylate) NDA #021977. U.S. Food and Drug Administration. 2007. Available from: www.accessdata.fda.gov/drugsatfda_ docs/nda/2007/021977s000TOC.cfm [Accessed 29 May 2009]
   Google Scholar
• Stanczak A, Ferra A. Prodrugs and soft drugs. Pharmacol Rep 2006;58:599-613
   PubMed Web of Science ®Google Scholar
• Da Prada M, Keller HH, Kettler PL, The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia 1984;40:1165-72
   PubMedGoogle Scholar
• Pereillo JM, Maftouh M, Andrieu A, Structure and stereochemistry of the active metabolite clopidogrel. Drug Metab Dispos 2002;30(11):1288-95
   PubMed Web of Science ®Google Scholar
• Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010;6:317-27
   PubMed Web of Science ®Google Scholar
• Jensen PS, Hinshaw SP, Kraemer HC, ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001;40(2):147-58
   PubMed Web of Science ®Google Scholar
• Wigal SB, Maltas S, Crinella F, Reading Performance as a Function of Treatment With Lisdexamfetamine Dimesylate in Elementary School Children Diagnosed With ADHD. J Atten Disord 2012;16(1):23-33
   PubMed Web of Science ®Google Scholar
• Wigal SB, Wigal T, Schuck S, Academic, behavioral and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2011;21(2):121-31
   PubMed Web of Science ®Google Scholar
• Shaywitz S, Shaywitz B, Wietecha L, Effect of atomoxetine on reading and phonological skills in children and adolescents with dyslexia or attention deficit/hyperactivity disorder and comorbid dyslexia. Poster presented at the 59th Annual Meeting of the American Academy of Child & Adolescent; October2012; San Francisco, CA
   Google Scholar
• Shreeram S, He JP, Kalaydilian A, Prevalence of enuresis and its association with attention-deficit/hyperactivity disorder among U.S. children: results from a nationally representative study. J Am Acad Child Adolesc Psychiatry 2009;48(1):35-41
   Google Scholar
• Zito JM, Safer DJ, dosReis S, Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000;283(8):1025-30
   PubMed Web of Science ®Google Scholar
• Zuvekas S, Vitiello B. Stimulant medication use in children: a 12-year perspective. Am J Psychiatry 2012;169(2):160-6
   PubMed Web of Science ®Google Scholar
• Lahey BB, Pelham WE, Loney J, Three-year predictive validity of DS-IV attention deficit hyperactivity disorder in children diagnosed at 4-6 years of age. Am J Psychiatry 2004;161(11):2014-20
   PubMed Web of Science ®Google Scholar
• Greenhill L, Kollins S, Abikoff H, Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006;45:1284-93
   PubMed Web of Science ®Google Scholar
• Wigal SB, Gupta S, Greenhill L, Pharmacokinetics of methylphenidate in preschoolers with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol 2007;17(2):153-64
   PubMedGoogle Scholar
• Wigal SB, Jun A, Wong AA, Does prior exposure to stimulants in children with ADHD impact physiological effects from lisdexamfetamine dimesylate? Postgraduate Med 2010;122(5):27-34
   PubMed Web of Science ®Google Scholar
• Wigal SB, Wong AA, Jun A, Adverse events in medication treatment-naive children with attention-Deficit/Hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate. J Child Adolesc Psychopharmacol 2012;22(2):149-56
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Newcorn J, Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage 2007;34(3):1182-90
   PubMed Web of Science ®Google Scholar
• Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry 2008;165(5):553-5
   Google Scholar
• Shire US, Inc. Vyvanse® (lisdexamfetamine dimesylate) C-II Prescribing Information. 2012. [ Accessed June 2012
   Google Scholar
• Elbe D, Macbride A, Reddy D. Focus on Lisdexamfetamine: a Review of its use in Child and Adolescent Psychiatry. J Can Acad Child Adolesc Psychiatry 2010;19(4):303-14
   Google Scholar
• Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 2010;19(4):303-14
   Google Scholar
• Najib J. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Clin Ther 2009;31(1):142-76
   PubMed Web of Science ®Google Scholar
• Shire US, Inc. ADDERALL XR® Medication Guide. C-II. 2011. [ Accessed June 2012
   Google Scholar
• Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single dose, crossover pharmacokinetic study. J Clin Pharmacol 2008;48(3):293-302
   PubMed Web of Science ®Google Scholar
• Haffey MB, Buckwalter M, Zhang P, Effects of omeprazole on the pharmacokinetic profiles of LDX and Mixed amphetamine salts extended release in adults. Clin Pharmacol 2009;121(5):11-29
   Google Scholar
• Vyanse(lisdexamfetamine dimesylate). Wayne, PA:Shire US Inc. 2008. Available from: http://www.vyvanse.comindexchild.aspWT.srch=1&src=1&mid=V000803&tid=1489731&KEYWORD=vyvanse&gelid-CIH_96fMvpcCFQObFQodCXofS [Accessed 29 July 2012]
   Google Scholar
• Krishnan SM, Stark JG. Multiple daily dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin 2008;24:33-40
   PubMed Web of Science ®Google Scholar
• Biederman J, Boellner SW, Childress A, Lisexamfetamine dimesylate and mixed amphetamines salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62:970-6
   PubMed Web of Science ®Google Scholar
• Biederman J, Krishnan S, Zhang Y, Efficacy and tolerability of lisdesamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double blind, forced dose, parallel group study. Clin Ther 2007;29:450-63
   PubMed Web of Science ®Google Scholar
• Wigal T, Brams M, Gasior M, Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct 2010;6:34
   PubMed Web of Science ®Google Scholar
• Ermer J, Homolka R, Martin P, Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol 2010;50:1001-11
   PubMed Web of Science ®Google Scholar
• Shire Canada Inc. Vyvanse® Product Monograph. Saint-Laurent, QC: Shire Canada Inc.; 2011
   Google Scholar
• Subcommittee on Attention-Deficit/hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of Attention-Deficit/hyperactivity Disorder in children and adolescents. Pediatrics 2011;128(5):1-16
   Google Scholar
• Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009;23(4):419-27
   PubMed Web of Science ®Google Scholar
• Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord 2006;10:92-111
   PubMedGoogle Scholar